COGNITION THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.55 USD | -1.92% |
|
+30.10% | +37.84% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 139.3 | 60.88 | 59.43 | 102.1 | - | - |
| Enterprise Value (EV) 1 | 139.3 | 60.88 | 59.43 | 102.1 | 102.1 | 102.1 |
| P/E ratio | -2.02 x | -2.31 x | -2.15 x | -2.62 x | -1.83 x | -1.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | -1.4 x | - | -1.81 x | -1.5 x | -1.03 x |
| FCF Yield | - | -71.7% | - | -55.3% | -66.6% | -97.1% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 22,036 | 28,989 | 32,122 | 40,058 | - | - |
| Reference price 2 | 6.320 | 2.100 | 1.850 | 2.550 | 2.550 | 2.550 |
| Announcement Date | 3/30/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -28.6 | -43.55 | -50.72 | -64.78 | -82.63 | -109.3 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -11.72 | -21.4 | -25.79 | -39.18 | -64.42 | -91.83 |
| Net income 1 | -12.07 | -16.25 | -21.4 | -25.79 | -39.18 | -64.42 | -91.83 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -7.350 | -3.130 | -0.9100 | -0.8600 | -0.9750 | -1.397 | -1.820 |
| Free Cash Flow 1 | - | - | -43.64 | - | -56.5 | -68 | -99.2 |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/7/21 | 3/30/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.81 | -9.413 | -12.21 | -12.62 | -9.3 | -8.973 | -11.82 | -14.74 | -15.19 | -14.1 | -16.27 | -16.91 | -17.57 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.339 | -3.713 | -5.877 | -6.625 | -5.182 | -6.172 | -4.726 | -6.749 | -8.141 | -9.151 | -8.127 | -9.317 | -10.39 |
| Net income 1 | -7.545 | -3.838 | -5.752 | -6.625 | -5.182 | -6.172 | -4.726 | -6.749 | -8.141 | -9.151 | -8.127 | -9.317 | -10.39 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4000 | -0.1700 | -0.2500 | -0.2900 | -0.2000 | -0.2100 | -0.1600 | -0.2200 | -0.2700 | -0.2700 | -0.2233 | -0.2033 | -0.1933 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/11/22 | 8/9/22 | 11/14/22 | 3/23/23 | 5/4/23 | 8/8/23 | 11/2/23 | 3/26/24 | 5/7/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -43.6 | - | -56.5 | -68 | -99.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 0.03 | 0.17 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 5/7/21 | 3/30/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.55
USD
Average target price
6.667
USD
Spread / Average Target
+161.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.84% | 102M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- CGTX Stock
- Financials Cognition Therapeutics, Inc.
